Balamurugan Tangiisuran

Prof. Dr. Balamurugan Tangiisuran

Universiti Sains Malaysia, George Town, Pulau Pinang, Malaysia
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2010 in Archives of internal medicine (1960)
Verified
Journal Article
Closed access
PDF file
GOGraziano Onder
Graziano Onder
MPMirko Petrovic
Mirko Petrovic
Balamurugan TangiisuranBalamurugan Tangiisuran
Balamurugan Tangiisuran
MMMarieke C. Meinardi
Marieke C. Meinardi
WMWinih P. Markito-Notenboom
Winih P. Markito-Notenboom
TCTischa J. M. van der Cammen
Tischa J. M. van der Cammen
Research from JAMA Internal Medicine — Development and Validation of a Score to Assess Risk of Adverse Drug Reactions Among In-Hospital Patients 65 Years or Older — The GerontoNet ADR Risk Score

1 March 2016 in Journal of Affective Disorders
Verified
Journal Article
Closed access
SHSiew Ching Ho
Siew Ching Ho
HCHuey Yi Chong
Huey Yi Chong
NCNathorn Chaiyakunapruk
Nathorn Chaiyakunapruk
Balamurugan TangiisuranBalamurugan Tangiisuran
Balamurugan Tangiisuran
SJSabrina Anne Jacob
Sabrina Anne Jacob

14 June 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SHSiew Ching Ho
Siew Ching Ho
SJSabrina Anne Jacob
Sabrina Anne Jacob
Balamurugan TangiisuranBalamurugan Tangiisuran
Balamurugan Tangiisuran
One of the major challenges in treating major depressive disorder (MDD) is patients’ non-adherence to medication. This study aimed to explore the barriers and facilitators of patients’ adherence to antidepressants among outpatients with MDD. Semi-structured and individual in-depth interviews were conducted among patients with MDD who were taking antidepressants, in the psychiatric clinic of a government-run hospital in Malaysia. Participants were purposively sampled from different genders and ethnicities. Interviews were conducted using a validated topic guide, and responses were audio-recorded, transcribed verbatim, checked, and analyzed using the grounded theory approach. A total of 30 patients were interviewed. Forty different themes and sub-themes were identified which were conceptually divided into two distinct categories related to barriers and facilitators to adherence. The barriers were: patient-specific, medication-specific, healthcare provision and system, social-cultural, and logistics. The facilitators were: having insight, perceived health benefits, regular activities, patient-provider relationship, reminders, and social support networks. Patient-specific barriers and medication side effects were the major challenges for adhering to treatment. Perceived health benefits and having insight on the need for treatment were the most frequently cited facilitators. Targeted interventions should be developed to address the key barriers, and promote measures to facilitate adherence in this group of patients.

30 October 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Balamurugan TangiisuranBalamurugan Tangiisuran
Balamurugan Tangiisuran
GSGreg Scutt
Greg Scutt
JSJennifer Stevenson
Jennifer Stevenson
JWJuliet Wright
Juliet Wright
GOG Onder
G Onder
GDGraham Davies
Graham Davies
Older patients are at an increased risk of developing adverse drug reactions (ADR). Of particular concern are the oldest old, which constitute an increasingly growing population. Having a validated clinical tool to identify those older patients at risk of developing an ADR during hospital stay would enable healthcare staff to put measures in place to reduce the risk of such an event developing. The current study aimed to (1) develop and (2) validate an ADR risk prediction model. We used a combination of univariate analysis and multivariate binary logistic regression to identify clinical risk factors for developing an ADR in a population of older people from a UK teaching hospital. The final ADR risk model was then validated in a European population (European dataset). Six-hundred-ninety patients (median age 85 years) were enrolled in the development stage of the study. Ninety-five reports of ADR were confirmed by independent review in these patients. Five clinical variables were identified through multivariate analysis and included in our final model; each variable was attributed a score of 1. Internal validation produced an AUROC of 0.74, a sensitivity of 80%, and specificity of 55%. During the external validation stage the AUROC was 0.73, with sensitivity and specificity values of 84% and 43% respectively. We have developed and successfully validated a simple model to use ADR risk score in a population of patients with a median age of 85, i.e. the oldest old. The model is based on 5 clinical variables (≥8 drugs, hyperlipidaemia, raised white cell count, use of anti-diabetic agents, length of stay ≥12 days), some of which have not been previously reported.

24 May 2012 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
LCLi Li Chen
Li Li Chen
Balamurugan TangiisuranBalamurugan Tangiisuran
Balamurugan Tangiisuran
ASASRUL SHAFIE
ASRUL SHAFIE
AHAzmi Hassali
Azmi Hassali

6 May 2009 in Age and Ageing
Verified
Journal Article
Open access
PDF file
Balamurugan TangiisuranBalamurugan Tangiisuran
Balamurugan Tangiisuran
JWJuliet Wright
Juliet Wright
TCTischa Van der Cammen
Tischa Van der Cammen
CRChakravarthi Rajkumar
Chakravarthi Rajkumar
The use of medication among the elderly population has increased tremendously over the last decade. However, the benefits of medications are always accompanied by potential harm, even when prescribed at recommended doses based on approved guidelines. The elderly are particularly at increased risk of adverse drug reactions (ADR) [1] attributed in the main to polypharmacy and physiological changes affecting the pharmacokinetics and pharmacodynamics of many drugs or poor compliance due to cognitive impairment or depression.